We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Portable Monitor Detects Acute Respiratory Distress Syndrome

By LabMedica International staff writers
Posted on 22 Aug 2019
Print article
Image: Rapid breath analysis for acute respiratory distress syndrome diagnostics using a portable two-dimensional gas chromatography device (Photo courtesy of University of Michigan).
Image: Rapid breath analysis for acute respiratory distress syndrome diagnostics using a portable two-dimensional gas chromatography device (Photo courtesy of University of Michigan).
Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury, responsible for high mortality and long-term morbidity. As a dynamic syndrome with multiple etiologies, its timely diagnosis is difficult as is tracking the course of the syndrome.

Therefore, there is a significant need for early, rapid detection and diagnosis as well as clinical trajectory monitoring of ARDS. Timely diagnosis and tracking of ARDS are very challenging because the condition can alter and progress rapidly and has several possible causes.

Scientists at the University of Michigan (Ann Arbor, MI, USA) have developed a portable breath analyzer that can accurately and rapidly detect ARDS. The device promises to increase rates of survival and reduce healthcare costs for people with the potentially life threatening lung condition. They tested the technology on 48 volunteers who were receiving treatment at the University of Michigan hospital. Of the volunteers, 21 had ARDS and the others served as controls.

The device designed by the team was a fully automated portable two-dimensional gas chromatography device with high peak capacity (> 200 at the resolution of 1), high sensitivity (sub-ppb), rapid analysis capability (~ 30 minutes) and made in-house for on-site analysis of patients’ breath. The technology in the device uses gas chromatography to analyze nearly 100 molecules in exhaled breath. It captures a sample of breath through a tube that connects to a mechanical ventilator's exhalation port.

An algorithm based on machine learning, principal component analysis (PCA), and linear discriminant analysis (LDA) was developed. As compared to the adjudications done by physicians based on the Berlin criteria, the device and algorithm achieved an overall accuracy of 87.1% with 94.1% positive predictive value and 82.4% negative predictive value. The results of the analysis allowed doctors not only to test for ARDS but also to determine how far advanced the condition is. The device can also monitor treatment progress after diagnosis.

The scientists concluded that the high overall accuracy and high positive predicative value suggest that the breath analysis method can accurately diagnose ARDS. The ability to continuously and non-invasively monitor exhaled breath for early diagnosis, disease trajectory tracking, and outcome prediction monitoring of ARDS may have a significant impact on changing practice and improving patient outcomes. The study was published on August 1, 2019, in the journal Analytical and Bioanalytical Chemistry.

Related Links:
University of Michigan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more